Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.
Proton pump inhibitors are used to treat gastroesophageal reflux, a symptom common in pregnancy. The aim of this study was to systematically analyze the available data on the risk for malformations following use of these agents in the first trimester of pregnancy. Medline, EMBASE, published abstracts, and reference lists were searched for articles reporting on proton pump inhibitor use in pregnancy. Summary relative risks and 95% confidence intervals (95% CI) were calculated using the Mantel-Haenszel method. Five cohort studies met the inclusion criteria for this meta-analysis. With almost 600 exposed pregnancies, the overall relative risk was 1.18 with a 95%CI of 0.72-1.94. In conclusion, proton pump inhibitors do not present a major teratogenic risk when used in recommend doses. These data are reassuring for the countless patients who have used these agents in the early part of their pregnancies.
The Motherisk Program, Hospital for Sick Children, Toronto, Ontario, Canada.
Shekoufeh
S
Nikfar
Mohammad
M
Abdollahi
Myla E
ME
Moretti
Laura A
LA
Magee
Gideon
G
Koren
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D005260:Female; D005333:Fetus / Q000187:drug effects*; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D008431:Maternal-Fetal Exchange; D009853:Omeprazole / Q000009:adverse effects*; D010437:Peptic Ulcer / Q000188:drug therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D054328:Proton Pump Inhibitors
D054328:Proton Pump Inhibitors; D009853:Omeprazole